PRODUCT INFORMATION



Hellebrin

Item No. 21442

CAS Registry No.:	13289-18-4	
Formal Name:	3β-[(6-deoxy-4-O-β-D-glucopyranosyl-	0 //
	α-L-mannopyranosyl)oxy]-5β,14-	
	dihydroxy-19-oxo-bufa-20,22-dienolide	
Synonym:	NSC 93134	~ 1
MF:	C ₃₆ H ₅₂ O ₁₅	
FW:	724.8	
Purity:	≥99%	
Supplied as:	A solid	
Storage:	-20°C	HO
Stability:	≥4 years	
Special Conditions: Light sensitive		
Information represents the product encoding tions. Databased in a litical results are previded on each contingent of analysis		

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Hellebrin is supplied as a solid. A stock solution may be made by dissolving the hellebrin in water. The solubility of hellebrin in water is approximately 4 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Hellebrin is a cardiac glycoside that potently inhibits the Na⁺/K⁺-ATPase by binding to it and blocking its non-canonical function as a receptor for cardiac glycosides.^{1,2} Hellebrin has a higher affinity for the $\alpha_1\beta_1$ subunit of the Na⁺/K⁺-ATPase than the $\alpha_2\beta_1$ or $\alpha_3\beta_1$ complexes, in contrast to other cardiac glycosides.¹ This affinity for the $\alpha_1\beta_1$ complex correlates with its cancer cell growth inhibition (GI₅₀ = 6-58 nM in various human cancer cell lines). Hellebrin also induces caspase-dependent apoptosis in Jurkat T cells.³

References

- 1. Moreno, Y.B.L., Katz, A., Miklos, W., et al. Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na⁺/K⁺-ATPase. Mol. Cancer 12, 1-14 (2013).
- 2. Ogawa, H., Shinoda, T., Cornelius, F., et al. Crystal structure of the sodium-potassium pump (Na⁺,K⁺-ATPase) with bound potassium and ouabain. Proc. Natl. Acad. Sci. USA 106(33), 13742-13747 (2009).
- 3. Daniel, D., Süsal, C., Kopp, B., et al. Apoptosis-mediated selective killing of malignant cells by cardiac steroids: Maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. Int. Immunopharmacol. 3, 1791-1801 (2003).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/15/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM